Which has higher valuation and earnings, GILD or NTRA?

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44B 6.05 $8.51B -$2.67 N/A Natera $2.31B 20.56 -$208.16M -$1.36 N/A

Is GILD or NTRA more profitable?

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% Natera -7.11% -11.38% -7.87%

Does the media refer more to GILD or NTRA?

In the previous week, Gilead Sciences had 15 more articles in the media than Natera. MarketBeat recorded 34 mentions for Gilead Sciences and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Gilead Sciences' score of 1.05 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 24 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRTX or NTRA?

In the previous week, Vertex Pharmaceuticals had 11 more articles in the media than Natera. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Vertex Pharmaceuticals' score of 0.80 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 16 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer REGN or NTRA?

In the previous week, Regeneron Pharmaceuticals had 30 more articles in the media than Natera. MarketBeat recorded 49 mentions for Regeneron Pharmaceuticals and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Regeneron Pharmaceuticals' score of 0.65 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 19 Very Positive mention(s) 4 Positive mention(s) 22 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NTRA or ARGX?

argenex has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.56 -$208.16M -$1.36 N/A argenex $4.25B 14.50 $1.29B $26.04 37.80

Is NTRA or ARGX more profitable?

argenex has a net margin of 32.19% compared to Natera's net margin of -7.11%. argenex's return on equity of 43.59% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% argenex 32.19% 43.59% 36.66%

Does the media prefer NTRA or ARGX?

In the previous week, Natera had 13 more articles in the media than argenex. MarketBeat recorded 19 mentions for Natera and 6 mentions for argenex. Natera's average media sentiment score of 1.14 beat argenex's score of 0.83 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, MRNA or NTRA?

Natera has higher revenue and earnings than Moderna. Natera is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 29.57 -$2.82B -$7.99 N/A Natera $2.31B 20.56 -$208.16M -$1.36 N/A

Is MRNA or NTRA more profitable?

Natera has a net margin of -7.11% compared to Moderna's net margin of -141.43%. Natera's return on equity of -11.38% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Natera -7.11% -11.38% -7.87%

Does the media refer more to MRNA or NTRA?

In the previous week, Moderna had 7 more articles in the media than Natera. MarketBeat recorded 26 mentions for Moderna and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Moderna's score of 0.56 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Natera (NTRA) Competitors

$328.93 +2.79 (+0.86%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$326.00 -2.94 (-0.89%)

As of 09/11/2026 07:47 PM Eastern

Compare

NTRA vs. GILD, VRTX, REGN, ARGX, and MRNA

Should you buy Natera stock or one of its competitors? Natera's main competitors and comparable companies include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), argenex (ARGX), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Natera compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Gilead Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Natera	-7.11%	-11.38%	-7.87%

Gilead Sciences presently has a consensus price target of $158.78, suggesting a potential upside of 10.48%. Natera has a consensus price target of $330.83, suggesting a potential upside of 0.58%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Gilead Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Gilead Sciences had 15 more articles in the media than Natera. MarketBeat recorded 34 mentions for Gilead Sciences and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Gilead Sciences' score of 1.05 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	24 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.05	$8.51B	-$2.67	N/A
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Gilead Sciences beats Natera on 9 of the 17 factors compared between the two stocks.

How does Natera compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.90	$3.95B	$17.18	30.00
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vertex Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Natera's net margin of -7.11%. Vertex Pharmaceuticals' return on equity of 23.09% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Natera	-7.11%	-11.38%	-7.87%

Vertex Pharmaceuticals presently has a consensus price target of $570.83, indicating a potential upside of 10.75%. Natera has a consensus price target of $330.83, indicating a potential upside of 0.58%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Vertex Pharmaceuticals had 11 more articles in the media than Natera. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Vertex Pharmaceuticals' score of 0.80 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	16 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Natera on 11 of the 17 factors compared between the two stocks.

How does Natera compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Regeneron Pharmaceuticals currently has a consensus target price of $802.18, suggesting a potential upside of 2.65%. Natera has a consensus target price of $330.83, suggesting a potential upside of 0.58%. Given Regeneron Pharmaceuticals' higher possible upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Natera's net margin of -7.11%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Natera	-7.11%	-11.38%	-7.87%

In the previous week, Regeneron Pharmaceuticals had 30 more articles in the media than Natera. MarketBeat recorded 49 mentions for Regeneron Pharmaceuticals and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Regeneron Pharmaceuticals' score of 0.65 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	19 Very Positive mention(s)	4 Positive mention(s)	22 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.61	$4.50B	$40.46	19.32
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

Summary

Regeneron Pharmaceuticals beats Natera on 10 of the 17 factors compared between the two stocks.

How does Natera compare to argenex?

Natera (NASDAQ:NTRA) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, Natera had 13 more articles in the media than argenex. MarketBeat recorded 19 mentions for Natera and 6 mentions for argenex. Natera's average media sentiment score of 1.14 beat argenex's score of 0.83 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 32.19% compared to Natera's net margin of -7.11%. argenex's return on equity of 43.59% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
argenex	32.19%	43.59%	36.66%

Natera currently has a consensus target price of $330.83, indicating a potential upside of 0.58%. argenex has a consensus target price of $1,158.61, indicating a potential upside of 17.70%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

argenex has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A
argenex	$4.25B	14.50	$1.29B	$26.04	37.80

Natera has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

99.9% of Natera shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

argenex beats Natera on 10 of the 16 factors compared between the two stocks.

How does Natera compare to Moderna?

Moderna (NASDAQ:MRNA) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

75.3% of Moderna shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Moderna had 7 more articles in the media than Natera. MarketBeat recorded 26 mentions for Moderna and 19 mentions for Natera. Natera's average media sentiment score of 1.14 beat Moderna's score of 0.56 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna currently has a consensus price target of $76.72, indicating a potential downside of 46.71%. Natera has a consensus price target of $330.83, indicating a potential upside of 0.58%. Given Natera's stronger consensus rating and higher probable upside, analysts plainly believe Natera is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Natera has a net margin of -7.11% compared to Moderna's net margin of -141.43%. Natera's return on equity of -11.38% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Natera	-7.11%	-11.38%	-7.87%

Natera has higher revenue and earnings than Moderna. Natera is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	29.57	-$2.82B	-$7.99	N/A
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Natera has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Summary

Natera beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Natera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRA vs. The Competition

Export

Metric	Natera	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.41B	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-241.86	8.38	214.57	20.80
Price / Sales	20.56	1,378.81	633.76	90.54
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	26.57	15.12	10.33	6.20
Net Income	-$208.16M	-$22.86M	$3.50B	$358.50M
7 Day Performance	0.23%	-4.34%	-3.32%	-2.35%
1 Month Performance	4.10%	-0.02%	-0.41%	-2.77%
1 Year Performance	95.20%	40.64%	19.21%	7.63%

Natera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRA Natera	2.1538 of 5 stars	$328.93 +0.9%	$330.83 +0.6%	+89.2%	$47.41B	$2.31B	N/A	6,140	Positive News Analyst Forecast
GILD Gilead Sciences	3.8818 of 5 stars	$150.99 flat	$158.04 +4.7%	+21.9%	$187.23B	$29.44B	N/A	17,000	Positive News Analyst Forecast
VRTX Vertex Pharmaceuticals	3.5643 of 5 stars	$546.12 flat	$569.52 +4.3%	+29.7%	$138.61B	$12.00B	31.79	6,400	Trending News Analyst Upgrade
REGN Regeneron Pharmaceuticals	3.82 of 5 stars	$827.72 flat	$800.36 -3.3%	+37.5%	$85.22B	$14.34B	20.46	15,410	Trending News Analyst Forecast
ARGX argenex	4.5471 of 5 stars	$1,033.15 flat	$1,158.61 +12.1%	+28.9%	$64.63B	$4.25B	39.68	1,863

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Natera (NTRA) Competitors

NTRA vs. GILD, VRTX, REGN, ARGX, and MRNA

How does Natera compare to Gilead Sciences?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Summary

How does Natera compare to argenex?

Summary

How does Natera compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Natera (NTRA) Competitors

NTRA vs. GILD, VRTX, REGN, ARGX, and MRNA

How does Natera compare to Gilead Sciences?

Which has more volatility and risk, GILD or NTRA?

Is GILD or NTRA more profitable?

Do analysts rate GILD or NTRA?

Does the media refer more to GILD or NTRA?

Which has higher valuation and earnings, GILD or NTRA?

Do institutionals & insiders have more ownership in GILD or NTRA?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Which has preferable valuation and earnings, VRTX or NTRA?

Do institutionals and insiders believe in VRTX or NTRA?

Which has more volatility & risk, VRTX or NTRA?

Is VRTX or NTRA more profitable?

Do analysts rate VRTX or NTRA?

Does the media refer more to VRTX or NTRA?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Do analysts rate REGN or NTRA?

Do institutionals & insiders have more ownership in REGN or NTRA?

Which has more volatility and risk, REGN or NTRA?

Is REGN or NTRA more profitable?

Does the media prefer REGN or NTRA?

Which has better valuation and earnings, REGN or NTRA?

Summary

How does Natera compare to argenex?

Does the media prefer NTRA or ARGX?

Is NTRA or ARGX more profitable?

Do analysts rate NTRA or ARGX?

Which has higher valuation & earnings, NTRA or ARGX?

Which has more volatility & risk, NTRA or ARGX?

Do insiders & institutionals believe in NTRA or ARGX?

Summary

How does Natera compare to Moderna?

Do institutionals and insiders believe in MRNA or NTRA?

Does the media refer more to MRNA or NTRA?

Do analysts prefer MRNA or NTRA?

Is MRNA or NTRA more profitable?

Which has higher earnings and valuation, MRNA or NTRA?

Which has more volatility and risk, MRNA or NTRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools